Concepts (262)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging | 33 | 2018 | 1218 | 1.870 |
Why?
|
Dobutamine | 15 | 2018 | 43 | 1.260 |
Why?
|
Ventricular Function, Left | 17 | 2016 | 194 | 1.230 |
Why?
|
Magnetic Resonance Imaging, Cine | 10 | 2016 | 64 | 0.880 |
Why?
|
Ventricular Dysfunction, Left | 10 | 2016 | 136 | 0.870 |
Why?
|
Anthracyclines | 6 | 2016 | 51 | 0.730 |
Why?
|
Myocardial Contraction | 6 | 2015 | 55 | 0.700 |
Why?
|
Stroke Volume | 11 | 2016 | 278 | 0.620 |
Why?
|
Exercise Test | 9 | 2015 | 194 | 0.540 |
Why?
|
Cardiotonic Agents | 7 | 2015 | 39 | 0.500 |
Why?
|
Antibiotics, Antineoplastic | 4 | 2016 | 62 | 0.470 |
Why?
|
Myocardial Ischemia | 5 | 2018 | 83 | 0.460 |
Why?
|
Heart Failure | 9 | 2015 | 568 | 0.440 |
Why?
|
Coronary Vessels | 3 | 2010 | 147 | 0.430 |
Why?
|
Models, Cardiovascular | 2 | 2010 | 27 | 0.430 |
Why?
|
Music Therapy | 2 | 2008 | 6 | 0.420 |
Why?
|
Predictive Value of Tests | 17 | 2018 | 787 | 0.410 |
Why?
|
Middle Aged | 42 | 2018 | 10829 | 0.400 |
Why?
|
Myocardial Perfusion Imaging | 3 | 2016 | 24 | 0.390 |
Why?
|
Image Enhancement | 1 | 2010 | 70 | 0.370 |
Why?
|
Heart Ventricles | 4 | 2016 | 107 | 0.350 |
Why?
|
Infant Care | 1 | 2008 | 2 | 0.340 |
Why?
|
Aged | 33 | 2018 | 9487 | 0.340 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2016 | 242 | 0.340 |
Why?
|
Chest Pain | 4 | 2011 | 175 | 0.330 |
Why?
|
Female | 45 | 2018 | 18164 | 0.330 |
Why?
|
Infant, Premature | 1 | 2008 | 62 | 0.330 |
Why?
|
Humans | 53 | 2018 | 29093 | 0.330 |
Why?
|
Myocardial Infarction | 8 | 2015 | 412 | 0.320 |
Why?
|
Emergency Service, Hospital | 4 | 2013 | 430 | 0.320 |
Why?
|
Male | 43 | 2018 | 17807 | 0.320 |
Why?
|
Weight Gain | 1 | 2008 | 108 | 0.320 |
Why?
|
Cardiovascular Diseases | 5 | 2014 | 1013 | 0.310 |
Why?
|
Risk Factors | 18 | 2018 | 3531 | 0.290 |
Why?
|
Echocardiography, Stress | 4 | 2016 | 22 | 0.260 |
Why?
|
Myocardium | 6 | 2016 | 170 | 0.260 |
Why?
|
Ventricular Remodeling | 3 | 2016 | 52 | 0.250 |
Why?
|
Heart Diseases | 4 | 2011 | 97 | 0.250 |
Why?
|
Aged, 80 and over | 16 | 2018 | 3717 | 0.240 |
Why?
|
Time Factors | 12 | 2018 | 2001 | 0.230 |
Why?
|
Coronary Circulation | 3 | 2016 | 30 | 0.230 |
Why?
|
Cardiomyopathies | 2 | 2016 | 48 | 0.230 |
Why?
|
Contrast Media | 6 | 2015 | 123 | 0.230 |
Why?
|
Prospective Studies | 13 | 2018 | 2019 | 0.220 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2013 | 47 | 0.220 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2016 | 105 | 0.220 |
Why?
|
Heptanoic Acids | 2 | 2014 | 28 | 0.220 |
Why?
|
Pyrroles | 2 | 2014 | 55 | 0.210 |
Why?
|
Acute Coronary Syndrome | 3 | 2013 | 175 | 0.210 |
Why?
|
Blood Flow Velocity | 4 | 2011 | 59 | 0.210 |
Why?
|
Prognosis | 10 | 2018 | 1362 | 0.200 |
Why?
|
Organometallic Compounds | 3 | 2010 | 18 | 0.200 |
Why?
|
Leukemia | 2 | 2013 | 36 | 0.190 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 546 | 0.190 |
Why?
|
Aging | 4 | 2014 | 881 | 0.190 |
Why?
|
Adult | 18 | 2016 | 8420 | 0.180 |
Why?
|
Edema, Cardiac | 2 | 2016 | 13 | 0.180 |
Why?
|
Magnetic Resonance Angiography | 3 | 2014 | 64 | 0.170 |
Why?
|
Risk Assessment | 9 | 2018 | 1305 | 0.160 |
Why?
|
Aorta | 3 | 2009 | 103 | 0.160 |
Why?
|
Vasodilator Agents | 3 | 2014 | 54 | 0.160 |
Why?
|
Breast Neoplasms | 2 | 2014 | 666 | 0.150 |
Why?
|
Aortic Diseases | 2 | 2011 | 54 | 0.150 |
Why?
|
Sex Factors | 2 | 2016 | 631 | 0.150 |
Why?
|
Adiposity | 2 | 2016 | 191 | 0.150 |
Why?
|
Severity of Illness Index | 4 | 2015 | 863 | 0.150 |
Why?
|
Phantoms, Imaging | 2 | 2010 | 56 | 0.150 |
Why?
|
Age Factors | 6 | 2018 | 1108 | 0.140 |
Why?
|
Reproducibility of Results | 7 | 2015 | 726 | 0.140 |
Why?
|
Stress, Physiological | 2 | 2016 | 44 | 0.140 |
Why?
|
Patient Positioning | 1 | 2015 | 21 | 0.140 |
Why?
|
Exercise Tolerance | 2 | 2009 | 110 | 0.130 |
Why?
|
Intra-Abdominal Fat | 2 | 2016 | 61 | 0.130 |
Why?
|
Simvastatin | 1 | 2014 | 25 | 0.130 |
Why?
|
Tubulin Modulators | 1 | 2014 | 10 | 0.130 |
Why?
|
Survivors | 1 | 2016 | 145 | 0.130 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 28 | 0.120 |
Why?
|
Heart Rate | 4 | 2011 | 315 | 0.120 |
Why?
|
Prediabetic State | 1 | 2015 | 54 | 0.120 |
Why?
|
North Carolina | 6 | 2015 | 1423 | 0.120 |
Why?
|
Furosemide | 1 | 2014 | 6 | 0.120 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.120 |
Why?
|
Renal Circulation | 1 | 2014 | 13 | 0.120 |
Why?
|
Coronary Artery Disease | 2 | 2015 | 359 | 0.120 |
Why?
|
Polysomnography | 1 | 2013 | 32 | 0.120 |
Why?
|
Renal Artery | 1 | 2014 | 43 | 0.120 |
Why?
|
Renal Artery Obstruction | 1 | 2014 | 38 | 0.120 |
Why?
|
Manometry | 1 | 2013 | 19 | 0.120 |
Why?
|
Aorta, Thoracic | 2 | 2011 | 72 | 0.120 |
Why?
|
Angina Pectoris | 1 | 2013 | 19 | 0.120 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 126 | 0.110 |
Why?
|
Cardiology Service, Hospital | 1 | 2013 | 22 | 0.110 |
Why?
|
Disability Evaluation | 1 | 2014 | 211 | 0.110 |
Why?
|
Oxygen | 1 | 2014 | 139 | 0.110 |
Why?
|
Lymphoma | 1 | 2013 | 36 | 0.110 |
Why?
|
Heterocyclic Compounds | 2 | 2010 | 8 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 196 | 0.110 |
Why?
|
Cardiac Output | 2 | 2009 | 32 | 0.110 |
Why?
|
Adenoidectomy | 1 | 2012 | 2 | 0.110 |
Why?
|
Saline Solution, Hypertonic | 1 | 2012 | 2 | 0.110 |
Why?
|
Tonsillectomy | 1 | 2012 | 9 | 0.110 |
Why?
|
Esophageal pH Monitoring | 1 | 2012 | 5 | 0.110 |
Why?
|
Sodium Chloride | 1 | 2012 | 24 | 0.110 |
Why?
|
Rhinitis | 1 | 2012 | 11 | 0.110 |
Why?
|
Sinusitis | 1 | 2012 | 17 | 0.100 |
Why?
|
Atrial Function, Left | 1 | 2012 | 18 | 0.100 |
Why?
|
Ventricular Function, Right | 1 | 2011 | 15 | 0.100 |
Why?
|
Arteries | 2 | 2013 | 60 | 0.100 |
Why?
|
Hospital Costs | 1 | 2011 | 36 | 0.100 |
Why?
|
Pulmonary Edema | 1 | 2011 | 7 | 0.100 |
Why?
|
Health Expenditures | 1 | 2011 | 61 | 0.100 |
Why?
|
Perfusion Imaging | 1 | 2011 | 7 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 90 | 0.100 |
Why?
|
Patient Admission | 1 | 2011 | 53 | 0.100 |
Why?
|
Inpatients | 1 | 2011 | 64 | 0.100 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2010 | 9 | 0.100 |
Why?
|
Pulsatile Flow | 1 | 2010 | 25 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2014 | 3099 | 0.090 |
Why?
|
Abdominal Fat | 1 | 2010 | 46 | 0.090 |
Why?
|
Cerebrovascular Circulation | 1 | 2011 | 95 | 0.090 |
Why?
|
Coronary Stenosis | 2 | 2016 | 28 | 0.090 |
Why?
|
Doxorubicin | 1 | 2010 | 55 | 0.090 |
Why?
|
Bicycling | 1 | 2009 | 13 | 0.090 |
Why?
|
Delivery of Health Care | 1 | 2011 | 142 | 0.090 |
Why?
|
Meglumine | 1 | 2009 | 3 | 0.090 |
Why?
|
Gadolinium DTPA | 1 | 2009 | 13 | 0.090 |
Why?
|
Adrenergic beta-Agonists | 1 | 2009 | 50 | 0.090 |
Why?
|
Computer Simulation | 1 | 2010 | 207 | 0.090 |
Why?
|
Women's Health Services | 1 | 2009 | 9 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 532 | 0.090 |
Why?
|
Atropine | 4 | 2011 | 16 | 0.090 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 125 | 0.090 |
Why?
|
Sucking Behavior | 1 | 2008 | 4 | 0.090 |
Why?
|
Therapeutic Touch | 1 | 2009 | 10 | 0.090 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2008 | 10 | 0.090 |
Why?
|
Infant Behavior | 1 | 2008 | 8 | 0.090 |
Why?
|
Endothelium, Vascular | 2 | 2016 | 145 | 0.080 |
Why?
|
Lower Extremity | 1 | 2009 | 93 | 0.080 |
Why?
|
Estrogen Replacement Therapy | 1 | 2010 | 182 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 39 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2013 | 709 | 0.080 |
Why?
|
Outpatients | 1 | 2008 | 49 | 0.080 |
Why?
|
Angina, Unstable | 3 | 2015 | 17 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2010 | 327 | 0.080 |
Why?
|
Heart Valve Diseases | 1 | 2007 | 25 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2007 | 28 | 0.070 |
Why?
|
Infant, Newborn | 1 | 2008 | 598 | 0.070 |
Why?
|
Leg | 1 | 2006 | 56 | 0.070 |
Why?
|
Stress, Psychological | 1 | 2008 | 208 | 0.070 |
Why?
|
Kidney | 1 | 2010 | 485 | 0.070 |
Why?
|
Hospitalization | 3 | 2018 | 417 | 0.070 |
Why?
|
Fibrosis | 2 | 2016 | 102 | 0.070 |
Why?
|
Linear Models | 3 | 2012 | 426 | 0.070 |
Why?
|
Disease Progression | 2 | 2018 | 572 | 0.070 |
Why?
|
Electrocardiography | 4 | 2013 | 562 | 0.070 |
Why?
|
Observer Variation | 3 | 2012 | 96 | 0.060 |
Why?
|
Echocardiography | 3 | 2011 | 140 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2016 | 1356 | 0.060 |
Why?
|
Hypertension | 1 | 2010 | 906 | 0.060 |
Why?
|
Child | 4 | 2012 | 2219 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2009 | 859 | 0.050 |
Why?
|
Intraoperative Complications | 1 | 2002 | 49 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2015 | 454 | 0.050 |
Why?
|
Length of Stay | 2 | 2013 | 292 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2014 | 720 | 0.050 |
Why?
|
Exercise | 1 | 2006 | 591 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 293 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2012 | 501 | 0.040 |
Why?
|
Oxygen Consumption | 2 | 2015 | 138 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2011 | 2108 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 85 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2009 | 82 | 0.040 |
Why?
|
Gadolinium | 2 | 2010 | 18 | 0.040 |
Why?
|
Single-Blind Method | 2 | 2012 | 165 | 0.040 |
Why?
|
Adenosine | 2 | 2011 | 41 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 29 | 0.040 |
Why?
|
Femoral Artery | 2 | 2009 | 44 | 0.040 |
Why?
|
Statistics as Topic | 2 | 2009 | 106 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2015 | 3111 | 0.030 |
Why?
|
Microcirculation | 1 | 2016 | 61 | 0.030 |
Why?
|
Young Adult | 2 | 2013 | 2402 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2016 | 226 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2016 | 637 | 0.030 |
Why?
|
Infant | 2 | 2008 | 969 | 0.030 |
Why?
|
Comorbidity | 1 | 2016 | 540 | 0.030 |
Why?
|
Vasodilation | 2 | 2006 | 87 | 0.030 |
Why?
|
Brachial Artery | 1 | 2014 | 66 | 0.030 |
Why?
|
Equipment Safety | 1 | 2013 | 20 | 0.030 |
Why?
|
Systole | 2 | 2005 | 87 | 0.030 |
Why?
|
Administration, Oral | 1 | 2014 | 169 | 0.030 |
Why?
|
Troponin I | 1 | 2013 | 17 | 0.030 |
Why?
|
Observation | 1 | 2013 | 23 | 0.030 |
Why?
|
Equipment Design | 1 | 2013 | 167 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 246 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2013 | 37 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2014 | 238 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 57 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2014 | 187 | 0.030 |
Why?
|
Troponin | 1 | 2013 | 79 | 0.030 |
Why?
|
Gastric Acidity Determination | 1 | 2012 | 4 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2012 | 30 | 0.030 |
Why?
|
Blood Glucose | 1 | 2015 | 466 | 0.030 |
Why?
|
Patient Readmission | 1 | 2013 | 105 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2011 | 23 | 0.030 |
Why?
|
Laryngoscopy | 1 | 2012 | 39 | 0.030 |
Why?
|
Survival Rate | 1 | 2014 | 795 | 0.030 |
Why?
|
Models, Economic | 1 | 2011 | 18 | 0.030 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2011 | 13 | 0.030 |
Why?
|
Cost Savings | 1 | 2011 | 32 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 896 | 0.030 |
Why?
|
Drug Costs | 1 | 2011 | 42 | 0.030 |
Why?
|
Spin Labels | 1 | 2011 | 23 | 0.020 |
Why?
|
Reference Standards | 1 | 2011 | 30 | 0.020 |
Why?
|
Echocardiography, Doppler | 1 | 2011 | 39 | 0.020 |
Why?
|
Incidence | 1 | 2014 | 1119 | 0.020 |
Why?
|
Acute Disease | 1 | 2011 | 239 | 0.020 |
Why?
|
Diastole | 1 | 2011 | 90 | 0.020 |
Why?
|
Self Administration | 1 | 2012 | 296 | 0.020 |
Why?
|
Heart | 1 | 2011 | 161 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2010 | 61 | 0.020 |
Why?
|
Software | 1 | 2011 | 109 | 0.020 |
Why?
|
Patient Discharge | 1 | 2011 | 168 | 0.020 |
Why?
|
Medroxyprogesterone | 1 | 2010 | 12 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 23 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 88 | 0.020 |
Why?
|
Adolescent | 2 | 2008 | 3254 | 0.020 |
Why?
|
Iliac Artery | 1 | 2009 | 46 | 0.020 |
Why?
|
Muscle Contraction | 1 | 2009 | 114 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 273 | 0.020 |
Why?
|
Body Composition | 1 | 2010 | 365 | 0.020 |
Why?
|
Body Mass Index | 1 | 2012 | 865 | 0.020 |
Why?
|
Obesity | 1 | 2016 | 1063 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 610 | 0.020 |
Why?
|
Affect | 1 | 2008 | 63 | 0.020 |
Why?
|
United States | 1 | 2016 | 3630 | 0.020 |
Why?
|
Postmenopause | 1 | 2010 | 397 | 0.020 |
Why?
|
Hemodynamics | 1 | 2008 | 148 | 0.020 |
Why?
|
Quality of Life | 1 | 2013 | 816 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 339 | 0.020 |
Why?
|
Pilot Projects | 1 | 2009 | 469 | 0.020 |
Why?
|
Pain Measurement | 1 | 2009 | 364 | 0.020 |
Why?
|
Transplants | 1 | 2007 | 22 | 0.020 |
Why?
|
Cohort Studies | 1 | 2011 | 1687 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 871 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2010 | 980 | 0.020 |
Why?
|
Reference Values | 1 | 2006 | 224 | 0.020 |
Why?
|
Rats | 1 | 2010 | 1604 | 0.020 |
Why?
|
Rest | 1 | 2006 | 49 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 494 | 0.020 |
Why?
|
Child, Preschool | 1 | 2008 | 1167 | 0.020 |
Why?
|
Ergometry | 1 | 2002 | 4 | 0.010 |
Why?
|
Heart Function Tests | 1 | 2002 | 4 | 0.010 |
Why?
|
Thigh | 1 | 2003 | 39 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2003 | 136 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2003 | 263 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 804 | 0.010 |
Why?
|
Death, Sudden, Cardiac | 1 | 2002 | 59 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2002 | 281 | 0.010 |
Why?
|
Radiography | 1 | 2003 | 353 | 0.010 |
Why?
|
Odds Ratio | 1 | 2002 | 447 | 0.010 |
Why?
|
Algorithms | 1 | 2003 | 462 | 0.010 |
Why?
|
Animals | 1 | 2010 | 7297 | 0.010 |
Why?
|